Navigation Links
Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients
Date:7/13/2011

teria and patient eligibility for the AdV HALT Trial is available at www.clinicaltrials.gov.

About Fast Track Designation

Chimerix has been granted two FDA Fast-Track Designations for CMX001: for the treatment of adenovirus disease and for the treatment of smallpox.  The FDA's "Fast Track" program is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious conditions and that demonstrate the potential to fill an unmet medical need.  The designation typically enables a Company to submit a New Drug Application (NDA) on a "rolling" basis with ongoing FDA review during the submission process. NDAs with Fast Track designation are also usually granted Priority Review by FDA at the time of NDA submission.

About Chimerix

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.  

The company's lead candidate, CMX001, is being developed as a potential broad spectrum, oral antiviral product for the treatment or prevention of life-threatening double-stranded DNA (dsDNA) viral diseases.  To date, more than 550 patients have been dosed with CMX001 in placebo-controlled clinical trials and open-label treatment protocols, including more than 250 individuals who have received CMX001 under Emergency Investigational New Drug Applications (EINDs)or as part of the CMX001-350 Open-Label Study to help treat life-threatening dsDNA viral diseases for which there were no other therapeutic options.

Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of CMV in adult hematopoietic stem cell transplant patients (CMX001-201); a Phase 2 study for the treatment of AdV infection in pediatric and adult hematopoietic stem cell transplant patients (AdV HALT Trial/CMX001-202)
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
2. Chimerix Joins International Network of Organizations to Cure Malaria
3. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
4. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
5. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
6. Chimerix Initiates Phase 1 Study of CMX157
7. Chimerix to Present at Upcoming Investor Conferences
8. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
9. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
10. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
11. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... April 27, 2015 Dr. Robert Hanzlik, ... chemical toxicity carries implications for advancing the creation of ... at National University , the second-largest private, nonprofit ... Dr. Hanzlik, a professor at the University of Kansas ... drug design, starts at 5 p.m. and takes place ...
(Date:4/27/2015)... 27, 2015 Deadly viruses such as ... resident of the University City Science Center's ... , With a $4.5 million Phase 2 SBIR ... Phelix Therapeutics is focused on therapies for ... The company is developing first-in-class protease inhibitors based on ...
(Date:4/27/2015)... -- Editor Note: For more ... . Investor-Edge has initiated coverage on ... LXRX ), Idera Pharmaceuticals Inc. (NASDAQ: IDRA ... Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI ), and ... report on Lexicon Pharma can be accessed at ...
(Date:4/27/2015)... 2015 SynGen Inc., a company that focuses ... harvest stem and progenitor cells from umbilical cord blood, ... that it has added three new members to its ... Business Units focus on product commercialization. ... Vice President and Chief Financial Officer.  Chuck was most ...
Breaking Biology Technology:Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 4Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 5SynGen Inc. Expands Its Management Team 2
... BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer ... for cells and tissues, today announced that it ... cryopreservation media for umbilical cord blood stem cells, ... market. BioLife Solutions, which will be exhibiting at ...
... University say they have discovered a simple method for ... nanostructure that some believe could replace silicon as the ... intense scientific research in recent years, graphene is a ... atoms arranged in a hexagonal lattice. It is the ...
... Drs. Samuel and Elenore Bogoch of BioRadar UK Ltd. announced ... of the EHEC lethal strains of E. Coli preceded the ... have been studied in laboratories in Germany and elsewhere since ... databases. Replikins are subsequences of the genome of an infectious ...
Cached Biology Technology:BioLife Solutions Now The Leading Supplier of Pre-Formulated GMP Cryopreservation Media for Umbilical Cord Blood Stem Cells 2BioLife Solutions Now The Leading Supplier of Pre-Formulated GMP Cryopreservation Media for Umbilical Cord Blood Stem Cells 3Northern Illinois University scientists find simple way to produce graphene 2Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 2Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 3
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
(Date:4/13/2015)... , April 13, 2015 ... TechSci Research, "Global Biometrics Market Forecast & Opportunities, 2020", ... a CAGR of around 14% till 2020. The ... for large scale implementation and review of biometric ... launch of new products with greater efficiency, are ...
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... learning more about how protein gets in the urine when ... blocks it. "We have known for a long time ... in diabetes," said Dr. David Pollock, renal physiologist at the ... that a new class of drugs called endothelin A receptor ...
... days of critical international discussion and debate, led by ... Clinical Densitometry (ISCD) and the International Osteoporosis Foundation (IOF), ... pertaining to the interpretation and use of FRAX in ... Tool (FRAX), with models for some 26 countries, is ...
... that applying a stem cell-infused patch together with overexpression ... to damaged cardiac tissue following heart attack and resulted ... also found that function improved more so than when ... that is being studied elsewhere. These findings are ...
Cached Biology News:Scientists learn more about how kidneys fail and how new drugs may intervene 2International discussions on FRAX smooth the way for implementation in clinical practice 2Stem cell patch may result in improved function following heart attack 2Stem cell patch may result in improved function following heart attack 3
... depletion cocktail is tailored to ... from suspensions of rat spleen ... the StemSep (or compatible 0.5 ... system. The CD4+ T cell ...
Preparation TW--Compatibility: Push-on end cap seals suitable up to 70 C only -Hybridization Tube for Model HB-1D -Comp Dim: 200 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-12...
Preparation TW--Compatibility: no end cap seals -Hybridization Tube for Hybrigene -Comp Dim: 240 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-15...
...
Biology Products: